Comparative Incidence of Urinary Tract Infections in Diabetic Women Treated with Dapagliflozin Versus Empagliflozin: A Double-Blind Randomized Clinical Trial
International Journal of Endocrinology and Metabolism · 15.07.2026 · 24 (4)
DOI: 10.5812/ijem-168824 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Endocrinology and Metabolism, online erschienen am 15.07.2026. Verfasst von Sara Kazem-Nadi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Faculty of Medicine, Aja University of Medical Sciences, Tehran, Iran. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Sodium-glucose cotransporter 2 (SGLT2) inhibitors, including dapagliflozin and empagliflozin, are widely used for glycemic control in type 2 diabetes but may affect the risk of urinary tract infection (UTI).
Objectives
This study compared the incidence of UTIs among women with diabetes treated with dapagliflozin versus empagliflozin.
Methods
In this randomized, double-blind clinical trial, 149 diabetic women aged ≥ 18 years were assigned to receive dapagliflozin 5 mg (n = 79) or empagliflozin 10 mg (n = 70) daily for three months. Fasting blood sugar (FBS), glycated hemoglobin (HbA1c), and serum creatinine (Cr) were measured at baseline and after treatment. Urinalysis and urine culture were used to confirm UTIs. Data were analyzed using SPSS version 28.0, with P < 0.05 considered statistically significant.
Results
The mean age was 62.7 ± 9.7 years, with no baseline differences between groups. UTIs occurred in 12 patients overall: 2 (2.5%) in the dapagliflozin group and 10 (14.3%) in the empagliflozin group (OR = 0.16; 95% CI, 0.03 - 0.74; P = 0.009). No significant intergroup differences were observed in FBS, HbA1c, or Cr levels.
Conclusions
Empagliflozin was associated with a higher short-term incidence of UTIs than dapagliflozin, despite similar metabolic outcomes. Monitoring for UTIs is recommended when prescribing SGLT2 inhibitors, particularly empagliflozin. Trial Registration: This trial is registered with the Iranian Registry of Clinical Trials (IRCT20250129064554N1).
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Faculty of Medicine, Aja University of Medical Sciences, Tehran, Iran.
- Department of Nephrology, Faculty of Medicine, Aja University of Medical Sciences, Tehran, Iran.
- Rajaie Cardiovascular Medical and Research Institute, Tehran, Iran.
- Clinical Research Development Unit, Imam Reza Hospital, Aja University of Medical Sciences, Tehran, Iran.
- Department of Endocrinology, Faculty of Medicine, Aja University of Medical Sciences, Tehran, Iran.
ORCID-Profile: Vahid Mousavi
Zitieren
APA
Kazem-Nadi, S., Keshtkari, S., Labbani-Motlagh, Z., & Mousavi, V. (2026). Comparative Incidence of Urinary Tract Infections in Diabetic Women Treated with Dapagliflozin Versus Empagliflozin: A Double-Blind Randomized Clinical Trial. International Journal of Endocrinology and Metabolism, 24(4). https://doi.org/10.5812/ijem-168824
Vancouver
Kazem-Nadi S, Keshtkari S, Labbani-Motlagh Z, Mousavi V. Comparative Incidence of Urinary Tract Infections in Diabetic Women Treated with Dapagliflozin Versus Empagliflozin: A Double-Blind Randomized Clinical Trial. International Journal of Endocrinology and Metabolism. 2026;24(4). doi:10.5812/ijem-168824
BibTeX
@article{KazemNadi2026,
author = {Kazem-Nadi, Sara and Keshtkari, Sara and Labbani-Motlagh, Zohre and Mousavi, Vahid},
title = {Comparative Incidence of Urinary Tract Infections in Diabetic Women Treated with Dapagliflozin Versus Empagliflozin: A Double-Blind Randomized Clinical Trial},
journal = {International Journal of Endocrinology and Metabolism},
year = {2026},
volume = {24},
number = {4},
doi = {10.5812/ijem-168824}
}
EUVIMED